Iloperidone (Fanapt) vs Paliperidone (Invega)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Iloperidone (Fanapt)
Marketed by Vanda Pharmaceuticals
NCT00254202 · Phase 3 · completed
This 4-week, randomized, double-blind Phase 3 trial (Study 2 in the FANAPT label, n=604) compared iloperidone 24 mg/day with placebo and with ziprasidone as an active control in acute schizophrenia. The primary endpoint was change in PANSS total score at day 28. The FDA label states that iloperidone 24 mg/day was superior to placebo on this endpoint, so the primary was met; efficacy appeared similar to ziprasidone. Sources: CT.gov posted results and the FANAPT label (openFDA).
Next expected readout: November 2027 · NCT06961968 (registry estimate)
Reported efficacy
Change From Baseline in Positive and Negative Symptom Scale Total (PANSS-T) Score (4 weeks): Change in PANSS total score at day 28: iloperidone 24 mg/day -12.0 (SE 1.03) vs placebo -7.1 (SE 1.48) vs ziprasidone -12.3 (SE 1.44) (CT.gov); iloperidone was superior to placebo on the primary (FANAPT label, Study 2). (met)
Result source: NCT00254202
Paliperidone (Invega)
Marketed by Johnson & Johnson
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: September 2027 · NCT04478838 (registry estimate)
Reported efficacy
Number of Participants With Relapse (Up to Day 730); Number of Participants With Treatment-emergent Adverse Events (TEAEs) (Up to Day 730): Number of Participants With Relapse (Up to Day 730): Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. 7/178 (not_applicable)
Result source: NCT04072575
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Iloperidone (Fanapt) | Paliperidone (Invega) |
|---|---|---|
| PANSS total, change | -12 vs -7.1−4.9 vs placeboNCT002542021 other result
| -9.8 vs -7.9−1.9 vs placeboNCT005183238 other results
|
| CGI-S, change | —Trial running · NCT06961968 | 0 vs 0±0 vs placeboNCT005183237 other results
|
| PANSS response | —Trial running · NCT06961968 | 76.8% vs 81.6%vs AripiprazoleNCT010090471 other result
|
| PSP, change | —Trial running · NCT06961968 | 17.1 vs 17.1vs AripiprazoleNCT010090473 other results
|
| Relapse (% of patients) | —Trial running · NCT06961968 | —Not posted · NCT03485417 |
PANSS total, change
- Iloperidone (Fanapt)
- -12 vs -7.1−4.9 vs placeboNCT00254202
1 other result
- 1.1 vs 12.4 NCT01291511
- Paliperidone (Invega)
- -9.8 vs -7.9−1.9 vs placeboNCT00518323
8 other results
- -17.3 vs -7.9 NCT00518323
- -13.8 vs -7.9 NCT00518323
- -9.1 vs 3.8 NCT00396565
- -19.3 vs -19.8 NCT01009047
- -25.6 vs -26.8 NCT01009047
- -13.5 vs -16.6 NCT00645099
- -15 vs -11.7 NCT00524043
- -8.9 vs -11.7 NCT00524043
CGI-S, change
- Iloperidone (Fanapt)
- —Trial running · NCT06961968
- Paliperidone (Invega)
- 0 vs 0±0 vs placeboNCT00518323
7 other results
- -1 vs 0 NCT00518323
- -1 vs 0 NCT00518323
- -0.4 vs 0.2 NCT00396565
- -1 vs -1 NCT01009047
- -1 vs -1 NCT01009047
- -0.5 vs -1 NCT00524043
- 0 vs -1 NCT00524043
PANSS response
- Iloperidone (Fanapt)
- —Trial running · NCT06961968
- Paliperidone (Invega)
- 76.8% vs 81.6%vs AripiprazoleNCT01009047
1 other result
- 67.9% vs 76.3% NCT01009047
PSP, change
- Iloperidone (Fanapt)
- —Trial running · NCT06961968
- Paliperidone (Invega)
- 17.1 vs 17.1vs AripiprazoleNCT01009047
3 other results
- 12.2 vs 12.2 NCT01009047
- 5.7 vs 1.6 NCT00524043
- 2.9 vs 1.6 NCT00524043
Relapse (% of patients)
- Iloperidone (Fanapt)
- —Trial running · NCT06961968
- Paliperidone (Invega)
- —Not posted · NCT03485417
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Iloperidone (Fanapt): 4 of 4 rows · Paliperidone (Invega): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Iloperidone (Fanapt) | Paliperidone (Invega) |
|---|---|---|
| Dropout rate | 34.6%a NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 24 more results51.3%Iloperidone NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 —Iloperidone (Cross-titration and S NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 —Iloperidone (Relapse-prevention Ph NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 30.3%Iloperidone Gradual Switch NCT01207414 · Phase 4 · registry result, not featured evidence 31.5%Iloperidone Immediate Switch NCT01207414 · Phase 4 · registry result, not featured evidence 18.8%625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 12.5%500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 13.3%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 6.7%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 6.7%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence | 41.2%b NCT00784238 · Phase 4 · registry result, not featured evidence show 35 more results48.4% NCT00761579 · Phase 4 · registry result, not featured evidence 36.4% NCT00761605 · Phase 4 · registry result, not featured evidence 20% NCT01387542 · Phase 4 · registry result, not featured evidence 11.3% NCT01362439 · Phase 4 · registry result, not featured evidence —Paliperidone ER - Extension Phase NCT01010776 · Phase 4 · registry result, not featured evidence —Paliperidone ER - Main Phase NCT01010776 · Phase 4 · registry result, not featured evidence 32.6% NCT01724359 · Phase 4 · registry result, not featured evidence 27.1% NCT01577186 · Phase 4 · registry result, not featured evidence 40.5% NCT00757705 · Phase 4 · registry result, not featured evidence 27.8% NCT01577160 · Phase 4 · registry result, not featured evidence —Paliperidone ER Phase NCT00535145 · Phase 4 · registry result, not featured evidence 25.4%Study Treatment NCT00535145 · Phase 4 · registry result, not featured evidence —TAU - Pali ER NCT00535145 · Phase 4 · registry result, not featured evidence 40%6 mg NCT00524043 · Phase 4 · registry result, not featured evidence 47%1.5 mg NCT00524043 · Phase 4 · registry result, not featured evidence 0%PALI ER Delayed Initiation NCT00535132 · Phase 4 · registry result, not featured evidence 0%PALI ER Immediate Initiation NCT00535132 · Phase 4 · registry result, not featured evidence —Paliperidone DB/Paliperidone Open- NCT01662310 · Phase 3 · registry result, not featured evidence —Paliperidone: Double Blind (DB) Ph NCT01662310 · Phase 3 · registry result, not featured evidence 36.4%Paliperidone (Double-blind)/Palipe NCT00488319 · Phase 3 · registry result, not featured evidence 50.2%Paliperidone (No Double-blind)/Pal NCT00488319 · Phase 3 · registry result, not featured evidence 38.5%Placebo/Paliperidone NCT00488319 · Phase 3 · registry result, not featured evidence 24.8% NCT01009047 · Phase 3 · registry result, not featured evidence 19.1% NCT01541371 · Phase 3 · registry result, not featured evidence 50% NCT00473434 · Phase 3 · registry result, not featured evidence 20.4% NCT00566631 · Phase 3 · registry result, not featured evidence — NCT00645099 · Phase 3 · registry result, not featured evidence 28.3%Paliperidone ER: Lack of Efficacy NCT01662648 · Phase 3 · registry result, not featured evidence 29.8%Paliperidone ER: Lack of Tolerabil NCT01662648 · Phase 3 · registry result, not featured evidence 22.9%Pali ER High NCT00518323 · Phase 3 · registry result, not featured evidence 35.2%Pali ER Low NCT00518323 · Phase 3 · registry result, not featured evidence 16.7%Pali ER Medium NCT00518323 · Phase 3 · registry result, not featured evidence 15.4% NCT01606228 · Phase 3 · registry result, not featured evidence 45.4% NCT01561898 · Phase 3 · registry result, not featured evidence 35.3% NCT00396565 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 24 more results14.5%Iloperidone NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 —Iloperidone (Cross-titration and S NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 —Iloperidone (Relapse-prevention Ph NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 10.4%Iloperidone Gradual Switch NCT01207414 · Phase 4 · registry result, not featured evidence 15%Iloperidone Immediate Switch NCT01207414 · Phase 4 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence | 4.8%b NCT00784238 · Phase 4 · registry result, not featured evidence show 35 more results5.3% NCT00761579 · Phase 4 · registry result, not featured evidence 6.7% NCT00761605 · Phase 4 · registry result, not featured evidence 7.5% NCT01387542 · Phase 4 · registry result, not featured evidence 0.8% NCT01362439 · Phase 4 · registry result, not featured evidence —Paliperidone ER - Extension Phase NCT01010776 · Phase 4 · registry result, not featured evidence —Paliperidone ER - Main Phase NCT01010776 · Phase 4 · registry result, not featured evidence 10.5% NCT01724359 · Phase 4 · registry result, not featured evidence 4.8% NCT01577186 · Phase 4 · registry result, not featured evidence 6.4% NCT00757705 · Phase 4 · registry result, not featured evidence 2.5% NCT01577160 · Phase 4 · registry result, not featured evidence —Paliperidone ER Phase NCT00535145 · Phase 4 · registry result, not featured evidence 2.6%Study Treatment NCT00535145 · Phase 4 · registry result, not featured evidence —TAU - Pali ER NCT00535145 · Phase 4 · registry result, not featured evidence 2.9%6 mg NCT00524043 · Phase 4 · registry result, not featured evidence 10.6%1.5 mg NCT00524043 · Phase 4 · registry result, not featured evidence —PALI ER Delayed Initiation NCT00535132 · Phase 4 · registry result, not featured evidence —PALI ER Immediate Initiation NCT00535132 · Phase 4 · registry result, not featured evidence —Paliperidone DB/Paliperidone Open- NCT01662310 · Phase 3 · registry result, not featured evidence —Paliperidone: Double Blind (DB) Ph NCT01662310 · Phase 3 · registry result, not featured evidence 1.7%Paliperidone (Double-blind)/Palipe NCT00488319 · Phase 3 · registry result, not featured evidence 9.5%Paliperidone (No Double-blind)/Pal NCT00488319 · Phase 3 · registry result, not featured evidence 2.6%Placebo/Paliperidone NCT00488319 · Phase 3 · registry result, not featured evidence 4.4% NCT01009047 · Phase 3 · registry result, not featured evidence 3.7% NCT01541371 · Phase 3 · registry result, not featured evidence 4.7% NCT00473434 · Phase 3 · registry result, not featured evidence 3.1% NCT00566631 · Phase 3 · registry result, not featured evidence — NCT00645099 · Phase 3 · registry result, not featured evidence 8.3%Paliperidone ER: Lack of Efficacy NCT01662648 · Phase 3 · registry result, not featured evidence 6.2%Paliperidone ER: Lack of Tolerabil NCT01662648 · Phase 3 · registry result, not featured evidence 2.1%Pali ER High NCT00518323 · Phase 3 · registry result, not featured evidence 1.9%Pali ER Low NCT00518323 · Phase 3 · registry result, not featured evidence 2.1%Pali ER Medium NCT00518323 · Phase 3 · registry result, not featured evidence 0.5% NCT01606228 · Phase 3 · registry result, not featured evidence 14.4% NCT01561898 · Phase 3 · registry result, not featured evidence 3.7% NCT00396565 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 0.7%a NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 24 more results—Iloperidone NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 3.3%Iloperidone (Cross-titration and S NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 4%Iloperidone (Relapse-prevention Ph NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 3.3%Iloperidone Gradual Switch NCT01207414 · Phase 4 · registry result, not featured evidence 2.7%Iloperidone Immediate Switch NCT01207414 · Phase 4 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 14.3%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 7.1%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence | 7.3%b NCT00784238 · Phase 4 · registry result, not featured evidence show 35 more results12.1% NCT00761579 · Phase 4 · registry result, not featured evidence 9.8% NCT00761605 · Phase 4 · registry result, not featured evidence 2.5% NCT01387542 · Phase 4 · registry result, not featured evidence 0.8% NCT01362439 · Phase 4 · registry result, not featured evidence 1.9%Paliperidone ER - Extension Phase NCT01010776 · Phase 4 · registry result, not featured evidence 6.5%Paliperidone ER - Main Phase NCT01010776 · Phase 4 · registry result, not featured evidence 7.4% NCT01724359 · Phase 4 · registry result, not featured evidence 7.7% NCT01577186 · Phase 4 · registry result, not featured evidence 3.7% NCT00757705 · Phase 4 · registry result, not featured evidence 0% NCT01577160 · Phase 4 · registry result, not featured evidence 2.4%Paliperidone ER Phase NCT00535145 · Phase 4 · registry result, not featured evidence —Study Treatment NCT00535145 · Phase 4 · registry result, not featured evidence 0%TAU - Pali ER NCT00535145 · Phase 4 · registry result, not featured evidence 7.1%6 mg NCT00524043 · Phase 4 · registry result, not featured evidence 10.6%1.5 mg NCT00524043 · Phase 4 · registry result, not featured evidence 4%PALI ER Delayed Initiation NCT00535132 · Phase 4 · registry result, not featured evidence 3.1%PALI ER Immediate Initiation NCT00535132 · Phase 4 · registry result, not featured evidence 4.3%Paliperidone DB/Paliperidone Open- NCT01662310 · Phase 3 · registry result, not featured evidence 3.1%Paliperidone: Double Blind (DB) Ph NCT01662310 · Phase 3 · registry result, not featured evidence 3.4%Paliperidone (Double-blind)/Palipe NCT00488319 · Phase 3 · registry result, not featured evidence 18.9%Paliperidone (No Double-blind)/Pal NCT00488319 · Phase 3 · registry result, not featured evidence 23.1%Placebo/Paliperidone NCT00488319 · Phase 3 · registry result, not featured evidence 6.2% NCT01009047 · Phase 3 · registry result, not featured evidence 0.2% NCT01541371 · Phase 3 · registry result, not featured evidence 42.2% NCT00473434 · Phase 3 · registry result, not featured evidence 7.8% NCT00566631 · Phase 3 · registry result, not featured evidence 8.8% NCT00645099 · Phase 3 · registry result, not featured evidence 6.8%Paliperidone ER: Lack of Efficacy NCT01662648 · Phase 3 · registry result, not featured evidence 4.9%Paliperidone ER: Lack of Tolerabil NCT01662648 · Phase 3 · registry result, not featured evidence 2.1%Pali ER High NCT00518323 · Phase 3 · registry result, not featured evidence 3.7%Pali ER Low NCT00518323 · Phase 3 · registry result, not featured evidence 2.1%Pali ER Medium NCT00518323 · Phase 3 · registry result, not featured evidence 2.1% NCT01606228 · Phase 3 · registry result, not featured evidence — NCT01561898 · Phase 3 · registry result, not featured evidence 3% NCT00396565 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | a headache 20.3% (placebo 19.7%) dizziness 17% (placebo 7.5%) sedation 12.7% (placebo 8.2%) NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 18 more resultsdizziness 11.6% (placebo 2.7%) somnolence 8.3% (placebo 0%) dry mouth 6.8% (placebo 0%) NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 dizziness 2.6% (placebo 2.7%) headache 2% (placebo 3.3%) insomnia 2% (placebo 4.7%) NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 dry mouth 17.9% dizziness 17.5% somnolence 14.2% NCT01207414 · Phase 4 · registry result, not featured evidence dizziness 22.3% dry mouth 20.8% insomnia 9.6% NCT01207414 · Phase 4 · registry result, not featured evidence 625 mg injection site pain 66.7% injection site induration 60% injection site swelling 20% NCT01348100 · Phase 1/2 · registry result, not featured evidence 625 mg headache 20% nasal congestion 20% anxiety 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 500 mg injection site pain 60% injection site induration 26.7% injection site swelling 20% NCT01348100 · Phase 1/2 · registry result, not featured evidence 500 mg nasal congestion 33.3% constipation 13.3% somnolence 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg back pain 7.1% constipation 7.1% headache 7.1% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg insomnia 20% headache 13.3% somnolence 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg constipation 14.3% headache 14.3% anxiety 7.1% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg headache 33.3% insomnia 33.3% dyspepsia 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg injection site pain 53.3% headache 26.7% nasal congestion 26.7% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg nasal congestion 40% headache 26.7% oropharyngeal pain 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 125 mg pruritus 50% throat irritation 50% upper respiratory tract infection 50% NCT01348100 · Phase 1/2 · registry result, not featured evidence 125 mg constipation 50% agitation 0% akathisia 0% NCT01348100 · Phase 1/2 · registry result, not featured evidence 50 mg blood creatine phosphokinase increased 50% agitation 0% akathisia 0% NCT01348100 · Phase 1/2 · registry result, not featured evidence 50 mg dizziness 50% headache 50% agitation 0% NCT01348100 · Phase 1/2 · registry result, not featured evidence | b akathisia 8.3% extrapyramidal disorder 4.8% insomnia 4.8% NCT00784238 · Phase 4 · registry result, not featured evidence show 33 more resultsakathisia 18.4% weight increased 15.3% muscle rigidity 7.4% NCT00761579 · Phase 4 · registry result, not featured evidence insomnia 12.4% akathisia 11.4% weight increased 9.3% NCT00761605 · Phase 4 · registry result, not featured evidence drowsiness 15% headache 15% insomnia 12.5% NCT01387542 · Phase 4 · registry result, not featured evidence insomnia 3% weight increase 3% extrapyramidal symptoms 2.3% NCT01362439 · Phase 4 · registry result, not featured evidence weight increased 12.6% insomnia 8.8% depression 4.4% NCT01010776 · Phase 4 · registry result, not featured evidence insomnia 14.9% anxiety 10.7% weight increased 10.7% NCT01010776 · Phase 4 · registry result, not featured evidence insomnia 25.3% akathisia 23.2% parkinsonism 15.8% NCT01724359 · Phase 4 · registry result, not featured evidence extrapyramidal disorder 11.7% upper respiratory tract infection 6.7% tremor 4.8% NCT01577186 · Phase 4 · registry result, not featured evidence insomnia 20.7% extrapyramidal disorder 13.7% anxiety 11.7% NCT00757705 · Phase 4 · registry result, not featured evidence insomnia 15.9% constipation 11.3% extrapyramidal disorder 9.6% NCT01577160 · Phase 4 · registry result, not featured evidence weight increased 6% headache 3.6% akathisia 2.4% NCT00535145 · Phase 4 · registry result, not featured evidence 6 mg headache 11.4% (placebo 15.6%) insomnia 10% (placebo 9.4%) tremor 10% (placebo 3.1%) NCT00524043 · Phase 4 · registry result, not featured evidence 1.5 mg insomnia 13.6% (placebo 9.4%) dizziness 7.6% (placebo 1.6%) headache 7.6% (placebo 15.6%) NCT00524043 · Phase 4 · registry result, not featured evidence constipation 9.1% insomnia 9.1% somnolence 8.1% NCT00535132 · Phase 4 · registry result, not featured evidence insomnia 9.2% headache 8.2% constipation 6.1% NCT00535132 · Phase 4 · registry result, not featured evidence constipation 4.3% (placebo 3.4%) akathisia 2.1% (placebo 5.1%) headache 2.1% (placebo 1.7%) NCT01662310 · Phase 3 · registry result, not featured evidence akathisia 4.7% (placebo 5.1%) nausea 3.1% (placebo 0%) tremor 3.1% (placebo 0%) NCT01662310 · Phase 3 · registry result, not featured evidence nasopharyngitis 15.3% somnolence 15.3% tremor 10.2% NCT00488319 · Phase 3 · registry result, not featured evidence weight increased 24.3% headache 18.9% somnolence 18.5% NCT00488319 · Phase 3 · registry result, not featured evidence somnolence 25.6% insomnia 17.9% anxiety 10.3% NCT00488319 · Phase 3 · registry result, not featured evidence akathisia 11.5% headache 10.6% somnolence 10.6% NCT01009047 · Phase 3 · registry result, not featured evidence akathisia 18.4% tremor 12.9% dystonia 8.7% NCT01541371 · Phase 3 · registry result, not featured evidence insomnia 15.6% headache 10.9% akathisia 9.4% NCT00473434 · Phase 3 · registry result, not featured evidence insomnia 23.1% tachycardia 8.5% headache 7.5% NCT00566631 · Phase 3 · registry result, not featured evidence insomnia 9.6% weight increased 9.6% headache 4.6% NCT00645099 · Phase 3 · registry result, not featured evidence insomnia 9.8% extrapyramidal disorder 6.6% headache 4.5% NCT01662648 · Phase 3 · registry result, not featured evidence insomnia 11.6% headache 4.1% nausea 3.9% NCT01662648 · Phase 3 · registry result, not featured evidence somnolence 20.8% (placebo 2%) akathisia 16.7% (placebo 0%) insomnia 12.5% (placebo 21.6%) NCT00518323 · Phase 3 · registry result, not featured evidence headache 9.3% (placebo 3.9%) insomnia 9.3% (placebo 21.6%) schizophrenia 9.3% (placebo 7.8%) NCT00518323 · Phase 3 · registry result, not featured evidence somnolence 14.6% (placebo 2%) akathisia 8.3% (placebo 0%) tremor 8.3% (placebo 0%) NCT00518323 · Phase 3 · registry result, not featured evidence insomnia 13.3% anemia 4.8% acute psychotic symptoms 1.6% NCT01606228 · Phase 3 · registry result, not featured evidence schizophrenia 16.4% (placebo 42.8%) insomnia 11.2% (placebo 10.1%) nasopharyngitis 10.4% (placebo 8%) NCT00396565 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 21 of these studies.
- bPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Iloperidone (Fanapt)
show 1 more result
show 3 more results
Paliperidone (Invega)
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 3 more results
show 2 more results
show 2 more results
show 25 more results
+ 68 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Iloperidone (Fanapt)'s landscape · Paliperidone (Invega)'s landscape